Clinical Trial Update: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis [Phase 3]

View source ↗

Summary

An open-label extension study (Phase 3) of saroglitazar magnesium in participants with primary biliary cholangitis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Saroglitazar Magnesium (saroglitazar magnesium)

Snippet

Sponsor: Zydus Therapeutics Inc. | Conditions: Primary Biliary Cholangitis | Phase 3 | Status: RECRUITING